Jiu Quan Shi

Researchers are studying adult patients who have had an acute ischemic stroke caused by blockage in medium-sized brain blood vessels. This trial aims to evaluate the effectiveness and safety of tenecteplase compared to standard medical care in patients treated within 4.5 to 24 hours after stroke symptoms begin. The study focuses on a specific group with confirmed medium vessel occlusions and uses imaging methods to select participants based on brain blood flow and damage. Participants will be randomly assigned to receive either a single intravenous dose of tenecteplase 0.25 mg per kilogram, up to 25 mg or standard medical treatment, which may include aspirin andor clopidogrel, following national stroke care guidelines. Treatments will be given between 4.5 and 24 hours after the patient was last seen well. The trial is controlled, randomized, and open-label with blinded evaluation of outcomes. During the study, participants will be monitored through clinical assessments including the National Institutes of Health Stroke Scale and the modified Rankin scale to measure disability at 90 days. Imaging tests such as CT or MRI perfusion scans will be used to evaluate brain blood flow and damage. Researchers will track neurological improvement, adverse events, bleeding events, and quality of life up to one year after treatment. The main outcome is the proportion of patients achieving minimal disability at 90 days post-treatment.

Researchers are evaluating the use of albumin combined with endovascular therapy in patients who have suffered an acute ischemic stroke in the anterior circulation. This prospective, multicenter, open-label, randomized controlled trial aims to verify the effectiveness and safety of adding albumin to the current standard endovascular treatment for this type of stroke. The study is sponsored by Capital Medical University and focuses on patients aged 18 to 80 years with specific stroke characteristics. Participants are randomly assigned to one of two groups one receiving albumin combined with endovascular treatment and the other receiving endovascular treatment alone. Albumin is given intravenously at a dose of 0.5 gkg up to 37.5 g on the first day and then daily on the second, third, and fourth days. Both groups receive acute stroke care and secondary prevention according to American stroke guidelines. Initial assessments include CT or MRI scans to locate the stroke and rule out bleeding, along with neurological and functional scoring. Throughout the study, patients undergo various evaluations such as the National Institutes of Health Stroke Scale NIHSS, Modified Rankin Scale mRS, Alberta Stroke Program Early CT Score ASPECTS, and quality of life assessments using standardized questionnaires. Vital signs and laboratory tests are monitored at baseline, with a 90-day follow-up conducted by telephone to assess recovery and outcomes. The primary measure is the proportion of patients achieving good functional recovery at 90 days after treatment.

Researchers are conducting a Phase 1b clinical trial to study anisodine hydrobromide in patients who have acute ischemic stroke and are undergoing endovascular therapy. The main goals are to assess the safety and tolerability of the drug and to find the appropriate dose for future studies. This open-label, non-randomized trial uses a dose-escalation design to identify the maximum tolerated dose and recommended dose for Phase II trials. Participants receive anisodine hydrobromide intravenously at one of four dose levels 1.0 mg, 1.5 mg, 2.0 mg, or 2.5 mg twice daily for seven consecutive days alongside standard endovascular therapy. The first dose is given before vascular recanalization but must not delay the endovascular procedure. The drug is diluted in sodium chloride solution and infused over about 60 minutes. All participants also receive standard care for stroke, including mechanical thrombectomy and other procedures as needed. Throughout the study, participants are closely monitored for safety and neurological outcomes. Researchers will measure safety events within eight days of the first dose, neurological changes within 24 hours, stroke infarct volume at day 8, and functional recovery at day 90 using the modified Rankin Scale. Additional assessments include brain hemorrhage events and all-cause mortality within 90 days. The total participation duration extends to approximately three months to capture these outcomes and ensure safety monitoring.